S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Codiak BioSciences Stock Forecast, Price & News

-0.84 (-6.44%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
49,207 shs
Average Volume
46,766 shs
Market Capitalization
$272.91 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CDAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Codiak BioSciences logo

About Codiak BioSciences

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.91 million
Book Value
$1.52 per share


Net Income
$-91.67 million
Net Margins
Pretax Margin




Free Float
Market Cap
$272.91 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.06 out of 5 stars

Medical Sector

554th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

89th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Codiak BioSciences (NASDAQ:CDAK) Frequently Asked Questions

Is Codiak BioSciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codiak BioSciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Codiak BioSciences stock.
View analyst ratings for Codiak BioSciences
or view top-rated stocks.

When is Codiak BioSciences' next earnings date?

Codiak BioSciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Codiak BioSciences

How were Codiak BioSciences' earnings last quarter?

Codiak BioSciences, Inc. (NASDAQ:CDAK) issued its earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.12. The firm earned $1.16 million during the quarter, compared to the consensus estimate of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 169.73% and a negative net margin of 425.30%.
View Codiak BioSciences' earnings history

What price target have analysts set for CDAK?

2 brokerages have issued twelve-month target prices for Codiak BioSciences' stock. Their forecasts range from $31.00 to $31.00. On average, they expect Codiak BioSciences' stock price to reach $31.00 in the next year. This suggests a possible upside of 154.1% from the stock's current price.
View analysts' price targets for Codiak BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Codiak BioSciences' key executives?

Codiak BioSciences' management team includes the following people:
  • Dr. Douglas Edward Williams, Pres, CEO & Director (Age 63, Pay $863.68k)
  • Ms. Yalonda Howze, Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 49, Pay $322.88k)
  • Ms. Linda Cathavina Bain CPA, CFO & Treasurer (Age 51)
  • Dr. Konstantin Konstantinov, Chief Technology Officer (Age 63) (LinkedIn Profile)
  • Dr. Sriram Sathyanarayanan Ph.D., Chief Scientific Officer (LinkedIn Profile)
  • Mr. Christopher J. M. Taylor, VP of Investor Relations & Corp. Communications
  • Ms. Nicole Barna, Sr. VP of HR (Age 47)
  • Dr. Benny Sorensen, Sr. VP of Strategic Projects (Age 47) (LinkedIn Profile)
  • Mr. Richard Brudnick, Chief Bus. Officer & Head of Corp. Strategy (Age 64)
  • Dr. Jennifer J. Wheler M.D., Chief Medical Officer

When did Codiak BioSciences IPO?

(CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO.

What is Codiak BioSciences' stock symbol?

Codiak BioSciences trades on the NASDAQ under the ticker symbol "CDAK."

Who are Codiak BioSciences' major shareholders?

Codiak BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.14%), Oracle Investment Management Inc. (3.13%), Ensign Peak Advisors Inc (2.12%), Franklin Resources Inc. (1.49%), Geode Capital Management LLC (1.03%) and Victory Capital Management Inc. (1.02%). Company insiders that own Codiak BioSciences stock include Benny Sorensen, Briggs Morrison, Konstantin Konstantinov and Sriram Sathyanarayanan.
View institutional ownership trends for Codiak BioSciences

Which major investors are selling Codiak BioSciences stock?

CDAK stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Ensign Peak Advisors Inc, California State Teachers Retirement System, New York State Common Retirement Fund, UBS Group AG, and Victory Capital Management Inc.. Company insiders that have sold Codiak BioSciences company stock in the last year include Benny Sorensen, Konstantin Konstantinov, and Sriram Sathyanarayanan.
View insider buying and selling activity for Codiak BioSciences
or view top insider-selling stocks.

Which major investors are buying Codiak BioSciences stock?

CDAK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Trellus Management Company LLC, Geode Capital Management LLC, Oracle Investment Management Inc., Bank of New York Mellon Corp, Metropolitan Life Insurance Co NY, Morgan Stanley, and Citigroup Inc..
View insider buying and selling activity for Codiak BioSciences
or or view top insider-buying stocks.

How do I buy shares of Codiak BioSciences?

Shares of CDAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codiak BioSciences' stock price today?

One share of CDAK stock can currently be purchased for approximately $12.20.

How much money does Codiak BioSciences make?

Codiak BioSciences has a market capitalization of $272.91 million and generates $2.91 million in revenue each year. The company earns $-91.67 million in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Codiak BioSciences have?

Codiak BioSciences employs 105 workers across the globe.

What is Codiak BioSciences' official website?

The official website for Codiak BioSciences is www.codiakbio.com.

How can I contact Codiak BioSciences?

The company can be reached via phone at 617-949-4100 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.